A recent study indicates that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds far faster than those who end conventional diet and exercise plans.
Research printed in a prominent health publication shows that while overweight individuals can lose a large proportion of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Users buying these drugs must be informed of the danger of rapid rebound weight gain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
That rate of regain means a return to original mass within about a year and a half.
Analyzing Therapies
The analysis, which reviewed 37 of studies involving thousands of patients, compared the effects of the injectable medications with other pills.
The team point out that individuals who lose weight through dieting usually see a slower creep back—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Nutrition scientists believe the mode of action of the drugs accounts for the accelerated weight return.
These medications copy a natural hormone called GLP-1, which moderates appetite.
"Artificially providing the hormone levels several times higher than normal may cause the body to produce less of its own natural GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating much more probable."
An Ongoing Disease?
Health authorities advise the jabs for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, considering the high risk of relapse, the treatment might need to be life-long.
This opinion is supported by drug manufacturers, who note that the results "emphasize the persistent nature of excess weight," comparing it to managing diseases like hypertension.
User Experiences
Users who have come off the jabs explain a intense return of hunger.
"I experienced a trigger activating and you become ravenous," said a patient.
The struggle is worsened if users have not developed permanent dietary or behavioural changes during treatment.
Widespread Use
Survey data show that a significant number of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Use is higher among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, researchers caution that while these medications are potent tools for weight loss, they are not a permanent cure and lasting health benefits relies on integrated lifestyle management.
